Immune Checkpoint Inhibitors in HNSCC: Changing the Treatment Landscape

ESMO Webinar Immune Checkpoint Inhibitors in HNSCC View Webinar

The programme is designed to offer an overview of research in this area and review the current status and future prospects of immunotherapy in HNSCC.

Immune Checkpoint Inhibitors in HNSCC: Changing the Treatment Landscape
Live from ESMO Congress 2019
Chair: Anthony TC Chan

Watch now*

*This content is only available to ESMO members. Find out more about becoming a member.

Welcome to the ESMO Webinar on Immune Checkpoint Inhibitors in HNSCC

It is with great pleasure that I invite you to participate in the ESMO Webinar entitled ‘Immune Checkpoint Inhibitors in HNSCC: Changing the Treatment Landscape’.  The webinar will be broadcast at 16:00 CET on 30 September from ESMO 2019 Congress in Barcelona.
  
Until recently there were limited treatment options for patients with advanced head and neck squamous cell carcinoma (HNSCC) when they progress on systemic chemotherapy.
  
However, immunotherapy is now an important option in that setting. Furthermore, positive data in first-line setting have recently emerged. Therefore, it is very important to continue research efforts to address questions on how best to incorporate these agents and move them earlier in clinical care of patients with HNSCC, along with optimising selection criteria for the treatment with immune checkpoint inhibitors.
  
I am delighted to announce the lectures by three distinguished experts in the field who will join me in this webinar.
During the webinar, we’ll cover topics such as a current place of immune checkpoint inhibitors in the management of patients with recurrent/metastatic HNSCC, role of biomarkers for selecting patients for immunotherapy, and research efforts on immunotherapy in the curative HNSCC setting. We will discuss various aspects of the potential and advantages of immune checkpoint inhibitors over conventional treatment modalities for HNSCC and prospects of their combinations.
  
The programme is designed to offer an overview of research in this area and review the current status and future prospects of immunotherapy in HNSCC.
  
I encourage you to join us in this stimulating new ESMO activity.

Anthony TC Chan, Department of Clinical Oncology The Chinese University of Hong Kong, China

Watch now*

*This content is only available to ESMO members. Find out more about becoming a member.

Programme

  • Welcome and Introduction, Anthony TC Chan, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
  • IO in the Management of Recurrent/Metastatic HNSCC, Jean-Pascal Machiels, Cliniques universitaires Saint-Luc, Université catholique de Louvain Brussels, Belgium
  • Biomarkers for IO in HNSCC, Amanda Psyrri, National Kapodistrian University of Athens, Attikon Hospital, Athens, Greece
  • Immunotherapy in the Curative HNSCC Setting, Ezra Cohen, UC San Diego Health, Moores Cancer Center, San Diego, USA
  • Q&A and Closing Remarks, Anthony TC Chan, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

Learning objectives

  • To understand the current evidence on treatment with immune checkpoint inhibitors in the recurrent/metastatic HNSCC 
  • To discuss the role of biomarkers in selection of the patients with HNSCC who might benefit from the treatment with immune checkpoint inhibitors 
  • To provide an update on ongoing clinical investigations and future outlook in terms of IO in the curative HNSCC setting 

Faculty

Name

Photo

Affiliation

Anthony TC Chan

chan-anthony no bg

Department of Clinical Oncology, The Chinese University of Hong Kong
Hong Kong, China

Ezra Cohen

cohen-ezra no bg

UC San Diego Health, Moores Cancer Center
San Diego, USA

Jean-Pascal Machiels

machiels-jean-pascal no bg

Cliniques universitaires Saint-Luc, Université catholique de Louvain
Brussels, Belgium

Amanda Psyrri

psyrri-amanda no bg

National Kapodistrian University of Athens, Attikon Hospital
Athens, Greece

Watch now*

*This content is only available to ESMO members. Find out more about becoming a member.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings